{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:52:49Z","timestamp":1787237569164,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The association between age and timing of antihypertensive treatment initiation and its effect on outcomes of patients with hypertension remain unclear. We investigated the impact of the time to antihypertensive therapy initiation for cardiovascular event primary prevention in an age-stratified analysis using data from a nationwide health claims database. This observational cohort study analyzed claim and health examination data recorded between January 1, 2005, and April 30, 2021, in the Japan Medical Data Center database. Patients with hypertension treated with antihypertensive agents were grouped by time (years) to therapy initiation: &lt;1 (reference group), 1\u20132, and \u22652. The primary outcome was a composite outcome encompassing cardiovascular death, acute coronary syndrome, heart failure, and cerebrovascular disease. The secondary outcome was all-cause mortality. Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals adjusted for the time to treatment (TTI) group, age, male sex, systolic blood pressure, smoking status, dyslipidemia, diabetes, and visceral obesity. Among 520,669 participants, TTI\u2009\u2265\u20091 year conferred significantly higher hazard ratios for primary outcomes than TTI\u2009&lt;\u20091 year in individuals aged \u226540 years. Hazard ratios (95% confidence intervals) for the primary outcome with TTI of 1\u20132 and &gt;2 years were 1.215 (1.073\u20131.375) and 1.296 (1.163\u20131.444) in those aged 40\u201349 years and 1.268 (1.144\u20131.406) and 1.341 (1.224\u20131.468) in those aged 50\u201359 years, respectively. TTI\u2009\u2265\u20092 years was an independent prognostic factor for the secondary outcome of all-cause mortality in those aged \u226540 years.<\/jats:p>","DOI":"10.1038\/s41440-025-02249-1","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T23:31:45Z","timestamp":1750289505000},"page":"2401-2412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic impact of the timing of antihypertensive medication initiation for hypertension detected at health screening on primary prevention of adverse cardiovascular events: Age-stratified real-world data analysis"],"prefix":"10.1038","volume":"48","author":[{"given":"Hiromasa","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"2249_CR1","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah GA, Fuster V, Murray CJL, Roth GA. Global Burden of Cardiovascular Diseases and Risks Collaborators. Global burden of cardiovascular diseases and risks, 1990\u20132022. J Am Coll Cardiol. 2023;82:2350\u2013473.","journal-title":"J Am Coll Cardiol"},{"key":"2249_CR2","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"GBD 2021 Risk Factors Collaborators.","year":"2024","unstructured":"GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2162\u2013203.","journal-title":"Lancet"},{"key":"2249_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","volume":"35","author":"NWS Chew","year":"2023","unstructured":"Chew NWS, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, et al. The global burden of metabolic disease: data from 2000 to 2019. Cell Metab. 2023;35:414\u201328.e3.","journal-title":"Cell Metab"},{"key":"2249_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(07)61299-9","volume":"370","author":"FH Messerli","year":"2007","unstructured":"Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370:591\u2013603.","journal-title":"Lancet"},{"key":"2249_CR5","doi-asserted-by":"crossref","unstructured":"Campbell NRC, Paccot Burnens M, Whelton PK, Angell SY, Jaffe MG, Cohn J, et al. World Health Organization guideline on pharmacological treatment of hypertension: policy implications for the region of the Americas. Lancet Reg Health Am. 2021; 2022: 9.","DOI":"10.1016\/j.lana.2022.100219"},{"key":"2249_CR6","first-page":"575","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34:575\u201384.","journal-title":"Can J Cardiol"},{"key":"2249_CR7","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/HYPERTENSIONAHA.118.12740","volume":"73","author":"K Kario","year":"2019","unstructured":"Kario K, Kanegae H, Tomitani N, Okawara Y, Fujiwara T, Yano Y, et al. Nighttime blood pressure measured by home blood pressure monitoring as an independent predictor of cardiovascular events in general practice. Hypertension. 2019;73:1240\u20138.","journal-title":"Hypertension"},{"key":"2249_CR8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2249_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41440-022-00924-1","volume":"45","author":"T Waki","year":"2022","unstructured":"Waki T, Miura K, Tanaka-Mizuno S, Ohya Y, Node K, Itoh H, et al. Prevalence of hypertensive diseases and treated hypertensive patients in Japan: A nationwide administrative claims database study. Hypertens Res. 2022;45:1123\u201333.","journal-title":"Hypertens Res"},{"key":"2249_CR10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jacc.2022.07.005","volume":"80","author":"PK Whelton","year":"2022","unstructured":"Whelton PK, Carey RM, Mancia G, Kreutz R, Bundy JD, Williams B. Harmonization of the American College of Cardiology\/American Heart Association and European Society of Cardiology\/European Society of Hypertension blood pressure\/hypertension guidelines: comparisons, reflections, and recommendations. J Am Coll Cardiol. 2022;80:1192\u2013201.","journal-title":"J Am Coll Cardiol"},{"key":"2249_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1161\/CIRCULATIONAHA.121.055177","volume":"146","author":"E Vidal-Petiot","year":"2022","unstructured":"Vidal-Petiot E. Thresholds for hypertension definition, treatment initiation, and treatment targets: recent guidelines at a glance. Circulation. 2022;146:805\u20137.","journal-title":"Circulation"},{"key":"2249_CR12","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"2249_CR13","first-page":"e484","volume":"2018","author":"PK Whelton","year":"2017","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2017;2018:e484\u2013e594.","journal-title":"Circulation"},{"key":"2249_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.948707","volume":"9","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Gao X, Jia HY, Li FR, Ye H. Influence of hypertension duration and blood pressure levels on cardiovascular disease and all-cause mortality: A large prospective cohort study. Front Cardiovasc Med. 2022;9:948707.","journal-title":"Front Cardiovasc Med"},{"key":"2249_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40801-022-00331-5","volume":"9","author":"J Fujinaga","year":"2022","unstructured":"Fujinaga J, Fukuoka T. A review of research studies using data from the administrative claims databases in Japan. Drugs Real World Outcomes. 2022;9:543\u201350.","journal-title":"Drugs Real World Outcomes"},{"key":"2249_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01722-5","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Iijima M, Togo K, Yonemoto N. Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. J Headache Pain. 2024;25:19.","journal-title":"J Headache Pain"},{"key":"2249_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s40121-023-00795-0","volume":"12","author":"T Umemura","year":"2023","unstructured":"Umemura T, Wattanakamolkul K, Nakayama Y, Takahashi Y, Sbarigia U, KyungHwa L, et al. Real-world epidemiology, clinical and economic burden of chronic hepatitis B in Japan: A retrospective study using JMDC claims database. Infect Dis Ther. 2023;12:1337\u201349.","journal-title":"Infect Dis Ther"},{"key":"2249_CR18","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/jdi.13887","volume":"13","author":"M Gouda","year":"2022","unstructured":"Gouda M, Arakawa K, Inagaki M, Ushirogawa Y. Effect of sodium-glucose cotransporter\u20092 inhibitor medication on new prescriptions of antihypertensives, antigout\/antihyperuricemics and antidyslipidemics in Japan: analysis using the JMDC Claims Database. J Diabetes Investig. 2022;13:1842\u201351.","journal-title":"J Diabetes Investig"},{"key":"2249_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","volume":"9","author":"T Laurent","year":"2022","unstructured":"Laurent T, Simeone J, Kuwatsuru R, Hirano T, Graham S, Wakabayashi R, et al. Context and considerations for use of two Japanese real-world databases in Japan: medical data vision and Japanese medical data center. Drugs Real World Outcomes. 2022;9:175\u201387.","journal-title":"Drugs Real World Outcomes"},{"key":"2249_CR20","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1161\/CIRCULATIONAHA.120.052624","volume":"143","author":"H Kaneko","year":"2021","unstructured":"Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, et al. Association of blood pressure classification using the 2017 American College of Cardiology\/American Heart Association blood pressure guideline with risk of heart failure and atrial fibrillation. Circulation. 2021;143:2244\u201353.","journal-title":"Circulation"},{"key":"2249_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1253\/circj.CJ-17-0811","volume":"82","author":"SP Nagar","year":"2018","unstructured":"Nagar SP, Rane PP, Fox KM, Meyers J, Davis K, Beaubrun A, et al. Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ J. 2018;82:1008\u201316.","journal-title":"Circ J"},{"key":"2249_CR22","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41440-024-01927-w","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Hoshide S, Mogi M. The need for a personalized \u201cimplementation hypertension\u201d strategy to facilitate the implementation of the new European Society of Hypertension (2023), European Society of Cardiology (2024) and the upcoming Japanese Society of Hypertension (2025) hypertension guidelines in clinical practice. Hypertens Res. 2024;47:3380\u20132.","journal-title":"Hypertens Res"},{"key":"2249_CR23","unstructured":"Ministry of Health, Labour and Walfare. Standard Medical Examination \/ Health Guidance Program. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000194155_00004.html. Accessed Jun 1 2025."},{"key":"2249_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5551\/jat.12.301","volume":"12","author":"Y Matsuzawa","year":"2005","unstructured":"Matsuzawa Y. Metabolic syndrome-definition and diagnostic criteria in Japan. J Atheroscler Thromb. 2005;12:301.","journal-title":"J Atheroscler Thromb"},{"key":"2249_CR25","unstructured":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253."},{"key":"2249_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/CLEP.S245555","volume":"12","author":"Y Ono","year":"2020","unstructured":"Ono Y, Taneda Y, Takeshima T, Iwasaki K, Yasui A. Validity of claims diagnosis codes for cardiovascular diseases in diabetes patients in Japanese Administrative Database. Clin Epidemiol. 2020;12:367\u201375.","journal-title":"Clin Epidemiol"},{"key":"2249_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1253\/circj.CJ-22-0566","volume":"87","author":"K Kanaoka","year":"2023","unstructured":"Kanaoka K, Iwanaga Y, Okada K, Terasaki S, Nishioka Y, Nakai M, et al. Validity of diagnostic algorithms for cardiovascular diseases in Japanese Health Insurance Claims. Circ J. 2023;87:536\u201342.","journal-title":"Circ J"},{"key":"2249_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1253\/circrep.CR-24-0178","volume":"7","author":"K Kario","year":"2025","unstructured":"Kario K, Akari S, Kanegae H. Cardiovascular events during treatment with xanthine oxidoreductase inhibitors in patients with gout and hyperuricemia in Japan\u3000- A JMDC Claims Database Study. Circ Rep. 2025;7:183\u201390.","journal-title":"Circ Rep"},{"key":"2249_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"2249_CR30","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1002\/sim.9136","volume":"40","author":"SF McGough","year":"2021","unstructured":"McGough SF, Incerti D, Lyalina S, Copping R, Narasimhan B, Tibshirani R. Penalized regression for left-truncated and right-censored survival data. Stat Med. 2021;40:5487\u2013500.","journal-title":"Stat Med"},{"key":"2249_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/pst.2257","volume":"22","author":"Y Jin","year":"2023","unstructured":"Jin Y, Ton TGN, Incerti D, Hu S. Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R. Pharm Stat. 2023;22:194\u2013204.","journal-title":"Pharm Stat"},{"key":"2249_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","volume":"395","author":"S Yusuf","year":"2020","unstructured":"Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155\u2008722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. Lancet. 2020;395:795\u2013808.","journal-title":"Lancet"},{"key":"2249_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. MICE: multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45:1\u201367.","journal-title":"J Stat Softw"},{"key":"2249_CR34","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1161\/HYP.0000000000000195","volume":"77","author":"DW Jones","year":"2021","unstructured":"Jones DW, Whelton PK, Allen N, Clark D 3rd, Gidding SS, Muntner P, et al. Management of Stage 1 hypertension in adults with a low 10-year risk for cardiovascular disease: filling a guidance gap: A scientific statement from the American Heart Association. Hypertension. 2021;77:e58\u2013e67.","journal-title":"Hypertension"},{"key":"2249_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","volume":"384","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration.","year":"2014","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591\u20138.","journal-title":"Lancet"},{"key":"2249_CR36","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"2249_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","volume":"178","author":"M Brunstr\u00f6m","year":"2018","unstructured":"Brunstr\u00f6m M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: A systematic review and meta-analysis. JAMA Intern Med. 2018;178:28\u201336.","journal-title":"JAMA Intern Med"},{"key":"2249_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/01.HYP.25.2.155","volume":"25","author":"RW Alexander","year":"1995","unstructured":"Alexander RW. Theodore Cooper memorial lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25:155\u201361.","journal-title":"Hypertension"},{"key":"2249_CR39","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1161\/HYPERTENSIONAHA.119.13827","volume":"74","author":"J Gronewold","year":"2019","unstructured":"Gronewold J, Kropp R, Lehmann N, Stang A, Mahabadi AA, K\u00e4lsch H, et al. Cardiovascular risk and atherosclerosis progression in hypertensive persons treated to blood pressure targets. Hypertension. 2019;74:1436\u201347.","journal-title":"Hypertension"},{"key":"2249_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1136\/hrt.2004.042473","volume":"91","author":"T Kahan","year":"2005","unstructured":"Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart. 2005;91:250\u20136.","journal-title":"Heart"},{"key":"2249_CR41","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329:1456\u201362.","journal-title":"N Engl J Med"},{"key":"2249_CR42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"2249_CR43","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1253\/circj.70.960","volume":"70","author":"Y Nakamura","year":"2006","unstructured":"Nakamura Y, Yamamoto T, Okamura T, Kadowaki T, Hayakawa T, Kita Y, et al. Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980-94. Circ J. 2006;70:960\u20134.","journal-title":"Circ J"},{"key":"2249_CR44","doi-asserted-by":"publisher","first-page":"e66116","DOI":"10.1371\/journal.pone.0066116","volume":"8","author":"N Ooba","year":"2013","unstructured":"Ooba N, Setoguchi S, Ando T, Sato T, Yamaguchi T, Mochizuki M, et al. Claims-based definition of death in Japanese claims database: validity and implications. PLoS ONE. 2013;8:e66116.","journal-title":"PLoS ONE"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02249-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:12:21Z","timestamp":1757196741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02249-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02249-1","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}